Insider Transactions in Q2 2025 at Emergent Bio Solutions Inc. (EBS)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 08
2025
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
464
-0.54%
|
$2,784
$6.63 P/Share
|
|
Jun 08
2025
|
Coleen Glessner EVP, Quality & Ethics, and CPL |
SELL
Payment of exercise price or tax liability
|
Direct |
1,249
-0.71%
|
$7,494
$6.63 P/Share
|
|
Jun 08
2025
|
William Hartzel SVP, Bioservices |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-1.07%
|
$7,002
$6.63 P/Share
|
|
Jun 08
2025
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,733
-0.91%
|
$16,398
$6.63 P/Share
|
|
May 23
2025
|
Keith Katkin Director |
SELL
Open market or private sale
|
Direct |
7,844
-8.32%
|
$47,064
$6.3 P/Share
|
|
May 13
2025
|
Joseph C Papa President and CEO |
BUY
Open market or private purchase
|
Direct |
60,000
+14.91%
|
$300,000
$5.83 P/Share
|
|
Apr 30
2025
|
Louis W Sullivan Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+19.83%
|
-
|
|
Apr 30
2025
|
Donald W De Golyer Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+19.12%
|
-
|
|
Apr 30
2025
|
Zsolt Harsanyi Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+21.76%
|
-
|
|
Apr 30
2025
|
Keith Katkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+26.74%
|
-
|
|
Apr 30
2025
|
Sujata Tyagi Dayal Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+26.08%
|
-
|
|
Apr 30
2025
|
Kathryn C Zoon Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+30.37%
|
-
|
|
Apr 30
2025
|
Neal Franklin Fowler Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+20.25%
|
-
|
|
Apr 30
2025
|
Marvin L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+27.99%
|
-
|
|
Apr 30
2025
|
Ronald Richard Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,403
+24.59%
|
-
|
|
Apr 07
2025
|
Coleen Glessner EVP, Quality & Ethics, and CPL |
SELL
Payment of exercise price or tax liability
|
Direct |
480
-0.27%
|
$1,920
$4.44 P/Share
|
|
Apr 07
2025
|
William Hartzel SVP, Bioservices |
SELL
Payment of exercise price or tax liability
|
Direct |
561
-0.51%
|
$2,244
$4.44 P/Share
|